United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting
Business Wire•13/10/2026•07:00 ET
0
Key Highlights
- ➤Ralinepag reduced clinical worsening risk across baseline low-risk profiles in phase 3 ADVANCE OUTCOMES
- ➤Nebulized treprostinil significantly reduced multiple disease progression events versus placebo in phase 3 TETON-2
- ➤PHINDER interim analyses showed numerically higher mortality risk scores for ILD, particularly IPF
- ➤DeciPHer-ILD interim data found poor hemodynamics, impaired functional class, and reduced exercise capacity
- ➤FDA accepted applications for ralinepag in PAH and nebulized treprostinil in IPF
Expert Statements
Franck Rahaghi, Chief Medical Officer, United Therapeutics
“CHEST offers the opportunity to share important insights about the composition and diverse needs of patients with PAH, PH-ILD, and IPF as we strive to improve care for these progressive, life-threatening diseases.”
Franck Rahaghi, Chief Medical Officer, United Therapeutics
“United Therapeutics is dedicated to improving outcomes in these disease areas by developing new treatment options and advancing research that can help lead to earlier screening and disease detection and improved understanding of treatment paradigms.”
Franck Rahaghi, Chief Medical Officer, United Therapeutics
“A number of our presentations at this year’s CHEST meeting, as well as our ‘Time to Look Closer’ symposium, are directed toward these essential goals.”
United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting
A pre-specified subgroup analysis from the phase 3 ADVANCE OUTCOMES study showed that ralinepag reduced the risk of clinical worsening in patients with pulmonary arterial hypertension (PAH), regardless of how many noninvasive low-risk criteria they met at baseline
Get started
Create a free account to read the full story.